CaboLife is a prospective, non-interventional observational study assessing the effectiveness and safety of cabozantinib in a real-world setting in patients with neuroendocrine tumors. The study includes adult patients with unresectable or metastatic, well-differentiated pancreatic or extra-pancreatic NET who have progressed after at least one prior systemic therapy (excluding somatostatin analogues). The primary endpoint is disease control rate (DCR) at 6 months based on radiologic assessments performed ?????? routine care. Treatment is administered according to standard clinical practice without randomization or protocol-mandated interventions. Key secondary endpoints include objective response rate (ORR) and changes in health-related quality of life measured by EORTC QLQ-C30.
CaboLife is a prospective observational study evaluating the medication cabozantinib in patients with neuroendocrine tumors. These tumors can occur in different parts of the body, and all participants have already received at least one prior treatment but their disease has continued to progress. The aim of the study is to understand how well the treatment works and how safe it is in routine clinical practice. Patients receive cabozantinib as part of their standard care, with no additional procedures required for the study. Doctors collect information on tumor response, duration of treatment, and side effects. The study also assesses how the treatment affects patients’ quality of life.
